Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Depreciation & Amortization (CF) (2019 - 2025)

aTYR PHARMA's Depreciation & Amortization (CF) history spans 7 years, with the latest figure at $166000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 0.6% year-over-year to $166000.0; the TTM value through Dec 2025 reached $664000.0, down 5.14%, while the annual FY2025 figure was $664000.0, 5.14% down from the prior year.
  • Depreciation & Amortization (CF) reached $166000.0 in Q4 2025 per ATYR's latest filing, up from $165000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $183000.0 in Q4 2023 to a low of $39000.0 in Q4 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $134800.0, with a median of $163000.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): tumbled 70.68% in 2022, then skyrocketed 369.23% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $133000.0 in 2021, then crashed by 70.68% to $39000.0 in 2022, then surged by 369.23% to $183000.0 in 2023, then dropped by 8.74% to $167000.0 in 2024, then fell by 0.6% to $166000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Depreciation & Amortization (CF) are $166000.0 (Q4 2025), $165000.0 (Q3 2025), and $166000.0 (Q2 2025).